LibyaTuberculosis profile
Population  2017 6.4 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.54 (0.31–0.82) 8.4 (4.9–13)
Mortality (HIV+TB only) 0.026 (0.016–0.038) 0.4 (0.25–0.6)
Incidence  (includes HIV+TB) 2.5 (1.6–3.7) 40 (25–58)
Incidence (HIV+TB only) 0.065 (0.041–0.096) 1 (0.64–1.5)
Incidence (MDR/RR-TB)** 0.12 (0.057–0.2) 1.8 (0.89–3.1)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.12 (0.11–0.13) 0.95 (0.71–1.2) 1.1 (0.79–1.4)
Males 0.13 (0.12–0.15) 1.3 (0.94–1.7) 1.5 (1–1.9)
Total 0.26 (0.22–0.29) 2.3 (1.4–3.2) 2.5 (1.6–3.7)
TB case notifications, 2017  
Total cases notified 1 363
Total new and relapse 1 363
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 59%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 54% (37–85)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.23 (0.11–0.38)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 35 3%
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  31
(15–47)
Estimated % of TB cases with MDR/RR-TB 3.7% (2–5.9) 21% (15–27)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 59% 1 131
Previously treated cases, excluding relapse, registered in 2016 14% 22
HIV-positive TB cases registered in 2016 46% 54
MDR/RR-TB cases started on second-line treatment in 2015    
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data